Devang Kantesaria, M.D.
Since February 2000, Dr. Kantesaria has worked closely with Dr. Moller and later with Dr. Ostro at TL Ventures. His role covers all aspects of the venture business including deal sourcing, due diligence, deal negotiation and closing, portfolio company development and Board of Directors duties. He has served or currently serves on the Board of Directors of four TL Ventures portfolio companies and as an observer on numerous others.
In addition to his five years of work as a biotechnology venture investor, Dr. Kantesaria brings a combination of clinical, scientific and financial expertise derived from his experiences as a physician, basic researcher and biotechnology and pharmaceutical consultant.
Dr. Kantesaria graduated from MIT in 1994 with a B.S. degree in Biology and received his M.D. degree from Harvard Medical School in 1998. While at M.I.T., Dr. Kantesaria was a research scientist at the Whitehead Institute and the M.I.T. Center for Cancer Research, and worked with prominent research groups in the areas of immunology and protein chemistry, which resulted in two notable peer-reviewed publications.
From 1998 to 2000, Dr. Kantesaria was a senior consultant at McKinsey & Company, where he helped senior management of large biotechnology and pharmaceutical companies with strategic and operational issues including drug marketing, product launch strategy, asset acquisitions and sales, post-merger management, and critical decisions on research and development projects.